AU3544599A - Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease - Google Patents

Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease

Info

Publication number
AU3544599A
AU3544599A AU35445/99A AU3544599A AU3544599A AU 3544599 A AU3544599 A AU 3544599A AU 35445/99 A AU35445/99 A AU 35445/99A AU 3544599 A AU3544599 A AU 3544599A AU 3544599 A AU3544599 A AU 3544599A
Authority
AU
Australia
Prior art keywords
cancer
therapy
autoimmune disease
monoclonal igm
radiolabeled monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35445/99A
Inventor
Paul E. Borchardt
Syed M. Quadri
Huibert M. Vriesendorp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MCA DEVELOPMENT BV
Original Assignee
HUIBERT M VRIESENDORP
MCA DEV BV
PAUL E BORCHARDT
SYED M QUADRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HUIBERT M VRIESENDORP, MCA DEV BV, PAUL E BORCHARDT, SYED M QUADRI filed Critical HUIBERT M VRIESENDORP
Publication of AU3544599A publication Critical patent/AU3544599A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU35445/99A 1998-01-16 1999-01-15 Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease Abandoned AU3544599A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US862098A 1998-01-16 1998-01-16
US09008620 1998-01-16
PCT/US1999/000857 WO1999036105A2 (en) 1998-01-16 1999-01-15 USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE

Publications (1)

Publication Number Publication Date
AU3544599A true AU3544599A (en) 1999-08-02

Family

ID=21732655

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35445/99A Abandoned AU3544599A (en) 1998-01-16 1999-01-15 Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease

Country Status (5)

Country Link
EP (1) EP1047457A2 (en)
JP (1) JP2002509122A (en)
AU (1) AU3544599A (en)
CA (1) CA2318231A1 (en)
WO (1) WO1999036105A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
CA2436092A1 (en) * 2001-01-29 2002-08-08 Idec Pharmaceutical Corporation Modified antibodies and methods of use
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
JP4762717B2 (en) 2003-10-09 2011-08-31 中外製薬株式会社 IgM high concentration stabilization solution
US20060127311A1 (en) * 2004-11-17 2006-06-15 Duke University Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
SI2211851T1 (en) * 2007-10-09 2014-11-28 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Laminin-1 for use in enhancing muscle regeneration after injury or for improving wound healing if administered systemically
KR102289054B1 (en) * 2019-03-29 2021-08-19 한국수력원자력 주식회사 Prevention of rheumatoid arthritis by low-dose ionizing radiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292868A (en) * 1989-05-26 1994-03-08 Akzo N.V. Chelating agents for attaching metal ions to proteins
JPH089553B2 (en) * 1989-06-19 1996-01-31 アクゾ・エヌ・ヴエー Radioimmunotherapy using alpha particle release
EP0590109A4 (en) * 1992-03-04 1995-04-19 Akzo Nv -i(IN VIVO) BINDING PAIR PRETARGETING.
CN1201005C (en) * 1996-05-22 2005-05-11 维文蒂阿生物技术股份有限公司 Antigen binding fragments that specifically detect cancer cells, nucleotindes encoding the fragments, and use thereof for the prophylaxis and detection of cancers

Also Published As

Publication number Publication date
JP2002509122A (en) 2002-03-26
CA2318231A1 (en) 1999-07-22
WO1999036105A2 (en) 1999-07-22
WO1999036105A9 (en) 1999-10-21
WO1999036105A3 (en) 2000-02-10
EP1047457A2 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
IL131539A0 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
IL136335A0 (en) Monoclonal human natural antibodies
HK1096974A1 (en) Antibody against human parathormone related peptides
EP1043335A4 (en) Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
AU1462300A (en) Human pan-hcv human monoclonal antibodies
ZA962527B (en) Radiolabeled peptides for diagnosis and therapy
AU5536196A (en) Cancer diagnosis and therapy based on mutations in tgf-beta receptors
AU1810899A (en) Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
EE9900179A (en) Use of conjugates in prostate cancer drugs
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
EP1178829A4 (en) Human monoclonal antibody
EP0831793A4 (en) Protein particles for therapeutic and diagnostic use
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
AU3544599A (en) Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease
GB9811598D0 (en) Diagnosis and treatment of cancer
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
PL325457A1 (en) Humanised antibodies effective against human fas
EP0977590A4 (en) Human monoclonal antibodies
NZ501742A (en) Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
GB9812550D0 (en) Tumour therapy and imaging
AU4499196A (en) Antibodies for use in cancer therapy and diagnosis
SI1157041T1 (en) Antibodies for cancer therapy and diagnosis
AU5279996A (en) Antibodies and their use in cancer therapy and diagnosis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase